Literature DB >> 11080238

Late onset heterozygous ornithine transcarbamylase deficiency mimicking complex partial status epilepticus.

M D Bogdanovic1, D Kidd, A Briddon, J S Duncan, J M Land.   

Abstract

A 57 year old woman with post-traumatic complex partial seizures was admitted because of recurrent episodes of altered mental state over the preceding 4 years, each lasting up to 5 days. There was a history of dietary protein intolerance since childhood and two of her daughters had died in the neonatal period from unexplained encephalopathies. In hospital she developed fluctuating confusion, amnesia, and sudden episodes of unresponsiveness. An EEG was consistent with complex partial status epilepticus but there was no response to benzodiazepines. Nasogastric feeding and sodium valproate were given and shortly afterwards she lapsed into a deep coma. Blood ammonia and urinary orotate were raised, and genetic testing confirmed that she was a carrier of a mutation in exon 3 of the ornithine transcarbamylase gene (C to T at position 92). Treatment with protein restriction, carnitine, and sodium phenylbutyrate led to a full recovery over a period of 3 months. To our knowledge this is the oldest age of onset yet described in a manifesting carrier. She is the fifth patient with heterozygous ornithine transcarbamylase deficiency reported to have had a severe reaction to sodium valproate. Hyperammonaemic encephalopathy should be considered in patients of any age who experience fluctuating confusion.

Entities:  

Mesh:

Year:  2000        PMID: 11080238      PMCID: PMC1737159          DOI: 10.1136/jnnp.69.6.813

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  8 in total

1.  Hyperammonaemic encephalopathy induced by a commercial very-low-energy diet in a neglected ornithine-carbamoyltransferase-deficient woman.

Authors:  S Vinzio; A E Perrin; E Forestier; J L Schlienger; B Goichot
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

2.  A case with hyperammonemic encephalopathy triggered by single dose valproate.

Authors:  S Ciftci; A Guler; E Deveci; N Celebisoy; N Yuceyar
Journal:  Neurol Sci       Date:  2016-07-19       Impact factor: 3.307

Review 3.  Epilepsy and inborn errors of metabolism in adults: a diagnostic approach.

Authors:  F Sedel; I Gourfinkel-An; O Lyon-Caen; M Baulac; J-M Saudubray; V Navarro
Journal:  J Inherit Metab Dis       Date:  2007-10-22       Impact factor: 4.982

Review 4.  The neuropsychiatry of inborn errors of metabolism.

Authors:  Mark Walterfang; Olivier Bonnot; Ramon Mocellin; Dennis Velakoulis
Journal:  J Inherit Metab Dis       Date:  2013-05-23       Impact factor: 4.982

Review 5.  Neurological implications of urea cycle disorders.

Authors:  A L Gropman; M Summar; J V Leonard
Journal:  J Inherit Metab Dis       Date:  2007-11-23       Impact factor: 4.982

6.  Cross-sectional observational study of 208 patients with non-classical urea cycle disorders.

Authors:  Corinne M Rüegger; Martin Lindner; Diana Ballhausen; Matthias R Baumgartner; Skadi Beblo; Anibh Das; Matthias Gautschi; Esther M Glahn; Sarah C Grünert; Julia Hennermann; Michel Hochuli; Martina Huemer; Daniela Karall; Stefan Kölker; Robin H Lachmann; Amelie Lotz-Havla; Dorothea Möslinger; Jean-Marc Nuoffer; Barbara Plecko; Frank Rutsch; René Santer; Ute Spiekerkoetter; Christian Staufner; Tamar Stricker; Frits A Wijburg; Monique Williams; Peter Burgard; Johannes Häberle
Journal:  J Inherit Metab Dis       Date:  2013-06-19       Impact factor: 4.982

7.  Non-Hyperammonemic valproate encephalopathy.

Authors:  Omar Farooq; Pervaiz M Zunga; Mohd I Dar; Abdul Q Rather; Samia Rashid; Javid Basu; Ishrat H Dar; Mohd Ashraf
Journal:  Ann Neurosci       Date:  2014-04

8.  Hyperammonemic Coma in an Adult due to Ornithine Transcarbamylase Deficiency.

Authors:  Daniel L Roberts; David A Galbreath; Bhavesh M Patel; Timothy J Ingall; Amer Khatib; Daniel J Johnson
Journal:  Case Rep Crit Care       Date:  2013-02-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.